Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 13, 2019 - Issue 11
Submit an article Journal homepage
1,131
Views
39
CrossRef citations to date
0
Altmetric
Drug Profile

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Satya DasDepartment of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USACorrespondence[email protected]
View further author information
,
Taymeyah Al-ToubahDepartment of GI Oncology, Moffitt Cancer Center, Tampa, FL, USAView further author information
,
Ghassan El-HaddadDepartment of Interventional Radiology and Nuclear Medicine, Moffitt Cancer Center, Tampa, FL, USAView further author information
&
Jonathan StrosbergDepartment of GI Oncology, Moffitt Cancer Center, Tampa, FL, USAView further author information
Pages 1023-1031 | Received 06 Sep 2019, Accepted 22 Oct 2019, Published online: 30 Oct 2019

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Kanchi Patell, Matthew Kurian, Jorge A. Garcia, Prateek Mendiratta, Pedro C. Barata, Angela Y. Jia, Daniel E. Spratt & Jason R. Brown. (2023) Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Review of Anticancer Therapy 23:7, pages 731-744.
Read now
Jayson Kemble, Eugene D. Kwon & R. Jeffrey Karnes. (2023) Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert Review of Anticancer Therapy 23:2, pages 177-185.
Read now
Xiuhua Lu, Shibin Yan, Kelly Ann Koral & Zhongguang Chen. (2021) Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy 21:9, pages 917-926.
Read now

Articles from other publishers (36)

Wujun Chen, Yudong Wu, Jie Wang, Wanpeng Yu, Xin Shen, Kai Zhao, Bing Liang, Xiaokun Hu, Shuai Wang, Hongfei Jiang, Xinlin Liu, Miao Zhang, Xiaohui Xing, Chao Wang & Dongming Xing. (2023) Clinical advances in TNC delivery vectors and their conjugate agents. Pharmacology & Therapeutics, pages 108577.
Crossref
Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, Alexander Haug, Guillaume P. Nicolas, Ben Pais, Catherine Ansquer, Jean-Mathieu Beauregard, Alexander McEwan, Michael Lassmann, Daniele Pennestri, Magali Volteau, Nat P. Lenzo & Rodney J. Hicks. (2023) A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 51:1, pages 183-195.
Crossref
Vahab Alamdari-palangi, Khojaste Rahimi Jaberi, Mahshid Shahverdi, Yasaman Naeimzadeh, Amir Tajbakhsh, Sahar Khajeh, Vahid Razban & Jafar Fallahi. (2023) Recent advances and applications of peptide–agent conjugates for targeting tumor cells. Journal of Cancer Research and Clinical Oncology 149:16, pages 15249-15273.
Crossref
Xiaobin Li, Junyu Liu, Haihong Chen, Yaxin Chen, Yi Wang, Can Yang Zhang & Xin-Hui Xing. (2023) Multi-functional engineered polypeptide-based drug delivery systems for improved cancer therapy. Green Chemical Engineering 4:2, pages 173-188.
Crossref
Martine Bocchini, Marcella Tazzari, Sara Ravaioli, Filippo Piccinini, Flavia Foca, Michela Tebaldi, Fabio Nicolini, Ilaria Grassi, Stefano Severi, Raffaele Adolfo Calogero, Maddalena Arigoni, Joerg Schrader, Massimiliano Mazza & Giovanni Paganelli. (2023) Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. Frontiers in Oncology 13.
Crossref
Typhanie Ladrière, Julie Faudemer, Elise Levigoureux, Damien Peyronnet, Cédric Desmonts & Jonathan Vigne. (2023) Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics 15:4, pages 1240.
Crossref
Margaret Wheless & Satya Das. (2023) Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer 22:1, pages 34-44.
Crossref
Michelle Felicia Lee & Chit Laa Poh. (2023) Strategies to improve the physicochemical properties of peptide-based drugs. Pharmaceutical Research 40:3, pages 617-632.
Crossref
Ragnar Bruvoll, Johan Blakkisrud, Lars Tore Mikalsen, James Connelly & Caroline Stokke. (2023) Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE. Cancers 15:4, pages 1134.
Crossref
June S. Wasser & David J. Greenblatt. (2023) Applying real-world data from expanded-access (“compassionate use”) patients to drug development. Journal of Clinical and Translational Science 7:1.
Crossref
Yuqi Yang, Shuhang Wang, Peiwen Ma, Yale Jiang, Keman Cheng, Yue Yu, Ning Jiang, Huilei Miao, Qiyu Tang, Funan Liu, Yan Zha & Ning Li. (2023) Drug conjugate-based anticancer therapy - Current status and perspectives. Cancer Letters 552, pages 215969.
Crossref
Yago Alcaina, Yanping Yang, Yogindra Vedvyas, Jaclyn E. McCloskey & Moonsoo M. Jin. (2022) SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. Scientific Reports 12:1.
Crossref
Jiao Ma, Xin Hu, Lanying Li, Zijuan Rao & Chunyin Zhang. (2022) Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Mo Wu, Wei Huang, Nan Yang & Yanyong Liu. (2022) Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Experimental Hematology & Oncology 11:1.
Crossref
Vivek P. Chavda, Hetvi K. Solanki, Majid Davidson, Vasso Apostolopoulos & Joanna Bojarska. (2022) Peptide-Drug Conjugates: A New Hope for Cancer Management. Molecules 27:21, pages 7232.
Crossref
Mohamad K. Elajami, Lorena P. Burton, Hisham F. Bahmad, Gerard Chaaya & Michael Schwartz. (2022) Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma. Current Oncology 29:10, pages 7552-7557.
Crossref
Rahul V. Parghane & Sandip Basu. (2022) 177Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor. Clinical Nuclear Medicine 47:10, pages 874-875.
Crossref
Christina Laschinsky, Ken Herrmann, Wolfgang Fendler, Michael Nader, Harald Lahner, Boris Hadaschik & Patrick Sandach. (2022) Onkologische Theranostik in der NuklearmedizinOncological theranostics in nuclear medicine. Die Radiologie 62:10, pages 875-884.
Crossref
Ebrahim S. Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie & Rodolfo Núñez. (2022) Targeted α -Emitter Therapy with 212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial . Journal of Nuclear Medicine 63:9, pages 1326-1333.
Crossref
Pascale Plas, Lorenzo Limana, Denis Carré, Amath Thiongane, Olivier Raguin, Rosalba Mansi, Florence Meyer-Losic & Stéphane Lezmi. (2022) Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours. Pharmaceuticals 15:9, pages 1085.
Crossref
Joseph Lau, Hwan Lee, Julie Rousseau, François Bénard & Kuo-Shyan Lin. (2022) Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies. Molecules 27:15, pages 4959.
Crossref
Christina Laschinsky, Ken Herrmann, Wolfgang Fendler, Michael Nader, Harald Lahner, Boris Hadaschik & Patrick Sandach. (2022) Onkologische Theranostik in der NuklearmedizinOncological theranostics in nuclear medicine. Die Onkologie 28:7, pages 612-622.
Crossref
Qi Shang, Yun Su, Faith Leslie, Mingjiao Sun & Feihu Wang. (2022) Advances in peptide-drug conjugate-based supramolecular hydrogel systems for local drug delivery. Medicine in Drug Discovery 14, pages 100125.
Crossref
Shejil Kumar, Mariah Melek & Peter Rohl. (2022) Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE. Frontiers in Endocrinology 13.
Crossref
Ziqi Li, Mariam S. Aboian, Xiaohua Zhu & Bernadette Marquez-Nostra. (2022) Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 14:9, pages 2103.
Crossref
Nazenin Ipek Işıkcı, Mohammad Abuqbeitah & Mustafa Demir. (2022) The Interference of Gamma Rays With Bone Mineral Density Measurements in 177Lu-PSMA and DOTATATE Therapy. Journal of Clinical Densitometry 25:2, pages 237-243.
Crossref
Lingaku Lee, Irene Ramos-Alvarez & Robert T. Jensen. (2022) Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers 14:5, pages 1250.
Crossref
Alessio RIZZO, Salvatore ANNUNZIATA & Massimo SALVATORI. (2022) Side effects of theragnostic agents currently employed in clinical practice. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 65:4.
Crossref
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, Philippe B Ruszniewski, Lisa Bodei, Andrew Hendifar, Erik Mittra, Edward M Wolin, James C Yao, Marianne E Pavel, Enrique Grande, Eric Van Cutsem, Ettore Seregni, Hugo Duarte, Germo Gericke, Amy Bartalotta, Maurizio F Mariani, Arnaud Demange, Sakir Mutevelic & Eric P Krenning. (2021) 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 22:12, pages 1752-1763.
Crossref
Jakob Lindberg, Johan Nilvebrant, Per-Åke Nygren & Fredrik Lehmann. (2021) Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 26:19, pages 6042.
Crossref
Yi-Shen Zhu, Kexing Tang & Jiayi Lv. (2021) Peptide–drug conjugate-based novel molecular drug delivery system in cancer. Trends in Pharmacological Sciences 42:10, pages 857-869.
Crossref
Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming & Ghassan El-Haddad. (2021) Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine 62:1, pages 69-72.
Crossref
Jianming Xu. (2021) Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Therapeutic Advances in Medical Oncology 13, pages 175883592110426.
Crossref
Franziska Briest, Eva J. Koziolek, Jakob Albrecht, Fränze Schmidt, Monique R. Bernsen, Joost Haeck, Anja A. Kühl, Dagmar Sedding, Teresa Hartung, Samantha Exner, Martina Welzel, Christian Fischer, Carsten Grötzinger, Winfried Brenner, Richard P. Baum & Patricia Grabowski. (2021) Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo. Neoplasia 23:1, pages 80-98.
Crossref
Bryce J. B. Nelson, Jan D. Andersson & Frank Wuest. (2020) Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics 13:1, pages 49.
Crossref
Samieh Asadian, Hamed Mirzaei, Bagher Aziz Kalantari, Mohamad Reza Davarpanah, Morteza Mohamadi, Anastasia Shpichka, Leila Nasehi, Hamidreza Aboulkheyr Es, Peter Timashev, Mustapha Najimi, Nematollah Gheibi, Moustapha Hassan & Massoud Vosough. (2020) β-radiating radionuclides in cancer treatment, novel insight into promising approach. Pharmacological Research 160, pages 105070.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.